J Clin Oncol: Efficacy and safety of pembrolizumab + GVD (gemcitabine, vinorelbine and liposomal adriamycin) in the second-line treatment of relapsed or refractory classic Hodgkin's lymphoma

Up to 25% of patients with classic Hodgkin’s lymphoma (cHL) develop relapse or refractory (rel/ref) progression after first-line treatment.
The standard treatment for these patients is second-line therapy (SLT) followed by high-dose therapy And autologous hematopoietic cell transplantation (HDT/AHCT) to consolidate
.

55% of patients who respond to second-line treatment can be cured by HDT/AHCT treatment

Up to 25% of patients with classic Hodgkin’s lymphoma (cHL) develop relapse or refractory (rel/ref) progression after first-line treatment.

This is a multi-center, investigator-initiated, single-arm, phase II study conducted by the Memorial Sloan Kettering Cancer Center and the Sylvester Comprehensive Cancer Center of the University of Miami
.

The patient received pembrolizumab+GVD regimen

This is a multi-center, investigator-initiated, single-arm, phase II study conducted by the Memorial Sloan Kettering Cancer Center and the Sylvester Comprehensive Cancer Center of the University of Miami

Research Overview

Research Overview

Of the 39 patients included, 41% were refractory, and 38% relapsed within 1 year of first-line treatment
.

Thirty-one patients received 2 cycles of pembro-GVD treatment, and 8 patients received 4 cycles of treatment

Of the 39 patients included, 41% were refractory, and 38% relapsed within 1 year of first-line treatment

Treatment-related adverse reactions

Treatment-related adverse reactions

In total, 9 of 39 patients (23%) required treatment delay, with a median time of 6 days (range 4-14 days)
.

Reasons for delayed treatment include elevated transaminases (n=4), skin rash (n=1), mucositis (n=1), neutropenia (n=1), and upper respiratory tract infection (n=2)

In total, 9 of 39 patients (23%) required treatment delay, with a median time of 6 days (range 4-14 days)

Among the 38 patients with evaluable efficacy, 35 patients (92%) received CR and 3 patients (8%) received PR after 2 cycles of pembro-GVD treatment

Efficacy evaluation

Among the 38 patients with evaluable efficacy, 36 patients (95%) underwent HDT/AHCT after 2 (n=30) or 4 (n=6) cycles of pembro-GVD
.

Thirteen patients (33%) received brentuximab vedotin maintenance treatment after HDT/AHCT treatment

Among the 38 patients with evaluable efficacy, 36 patients (95%) underwent HDT/AHCT after 2 (n=30) or 4 (n=6) cycles of pembro-GVD

In summary, pembrolizumab + GVD (gemcitabine, vinorelbine, and liposomal adriamycin) second-line treatment of relapsed or refractory classic Hodgkin’s lymphoma is an efficient and well-tolerated treatment plan.
It can effectively promote patients to receive HDT/AHCT treatment, thereby improving the prognosis
.
Pembrolizumab + GVD (gemcitabine, vinorelbine, and liposomal adriamycin) for second-line treatment of relapsed or refractory classic Hodgkin’s lymphoma is an efficient and well-tolerated treatment plan that can effectively Promote patients to receive HDT/AHCT treatment, thereby improving the prognosis
.
Pembrolizumab + GVD (gemcitabine, vinorelbine, and liposomal adriamycin) for second-line treatment of relapsed or refractory classic Hodgkin’s lymphoma is an efficient and well-tolerated treatment plan that can effectively Promote patients to receive HDT/AHCT treatment, thereby improving the prognosis
.

Original source:

Original source:

Alison J Moskowitz, Gunjan Shah, Heiko Schöder, et al.
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
J Clin Oncol.
2021 Jun.
25;JCO2101056.
: 10.
1200/JCO.
21.
01056.
Online ahead of print.

Alison J Moskowitz, Gunjan Shah, Heiko Schöder, et al.
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
J Clin Oncol.
2021 Jun.
25;JCO2101056.
: 10.
1200/JCO.
21.
01056.
Online ahead of print.
Leave a message here